British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to ...

GSK shares in London jumped 5% Thursday after the British drug giant said it has resolved most of the U.S. lawsuits it faced ...

The British drugmaker’s settlement with 10 separate law firms resolves 93% of all U.S. cases currently filed against GSK over claims its popular Zantac drug contained the carcinogen N ...

The deal settles 80,000 US court cases related to allegations that Zantac was contaminated with a suspected carcinogen.

Tens of thousands of Americans are in line to share $2.2bn (£1.7bn) after GSK agreed a settlement over claims its indigestion ...

GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer ...

GlaxoSmithKline (GSK) saw its shares jump more than 6% after the pharmaceutical giant announced a settlement of up to $2.2 ...

(Reuters) - GSK said on Wednesday it had reached agreements with ten plaintiff firms, representing 93% of U.S. state court ...

Class action and personal injury lawsuits have been filed in US courts after the Food and Drug Administration warned in 2019 that some ranitidine drugs including Zantac contained low levels of an ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on ...

ranitidine, turned into the potential carcinogen NDMA under certain conditions. The US Food and Drug Administration asked companies producing Zantac to remove all ranitidine-based drugs from the U ...